QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Researchers at UCLA found that adding a special radioactive drug before targeted radiation helped men with recurrent prostate cancer stay cancer-free much longer than with radiation alone. The treatment targets PSMA, a protein abundantly expressed on prostate cancer cells. The…
This study investigated potential racial differences in how effectively MRI PI-RADS scoring predicts prostate cancer, noting that the system was originally developed using predominantly White patient populations. Using data from the multi-institutional PREVENT trial, the researchers conducted a secondary analysis…
A recent study compared image quality and diagnostic performance of 5-Tesla (5T) versus 3-Tesla (3T) MRI in 67 patients with suspected prostate cancer. T wo radiologists independently reviewed images from both systems using qualitative and quantitative assessments. Histopathology from biopsy…
This study focused on men in Denmark who had a surgery called TURP (transurethral resection of the prostate), which is often done to treat problems with urination. Sometimes during this surgery, doctors discover prostate cancer, even though the patients didn’t…
Stacy Loeb, MD, MSc, PhD, (Hon), is a Professor of Urology and Population Health at NYU Langone Health and the Manhattan Veterans Affairs Hospital. She is double Board-certified in Urology and in Lifestyle Medicine. Dr. Stacy Loeb is an internationally…
Prostate cancer poses unique challenges for prediction and treatment due to its highly variable tumor behavior, both between different patients and within the same patient. Circulating tumor cells (CTCs) are cancer cells that detach from a primary tumor, travel…
Prostate cancer often depends on the androgen receptor (AR), a protein that promotes cancer cell growth. A common and dangerous stage of the disease is castration- resistant prostate cancer (CRPC), which continues to grow even after treatments that lower…
This study looked at whether a one-time invitation for a PSA test for prostate cancer helps men live longer. Over 415,000 men aged 50 to 69 in England and Wales participated in the study . Some were invited to…
Advanced prostate cancers respond to hormone therapy, but outcomes vary , and no predictive tests exist for informed treatment selection. To identify novel biomarker-treatment pairings, researchers examined the associations between biological pathways and 14- year survival outcomes of patients randomized…
The Urological Research Foundation supports research and patient education in prostate cancer. Every dollar spent focuses on these goals. To maximize research funding, the board recommends changing our format to reduce costs and be more eco-friendly . Starting with the…
"*" indicates required fields
